OrthoPediatrics Corp. develops and commercializes medical devices for pediatric orthopedics, with products used in trauma and deformity, scoliosis, sports medicine and related procedures. Company news commonly covers quarterly financial results, revenue by product category, domestic and international sales trends, cash-flow metrics and updates to financial guidance.
Recurring product and market updates include specialty bracing, spine and deformity correction systems, implants, instruments and enabling technologies for pediatric care. Announcements also include investor conference participation and portfolio additions such as hospital-based traction systems and other products aimed at children with orthopedic conditions.
OrthoPediatrics Corp. (NASDAQ: KIDS) has launched its 6.5mm/7.3mm Slipped Capital Femoral Epiphysis (SCFE) Cannulated Screw system after receiving FDA 510(k) clearance. This innovative system features fully and partially threaded screws designed specifically for pediatric patients, available in 2mm increments. The addition expands OrthoPediatrics' offerings, which now includes screws in multiple sizes to meet the needs of pediatric orthopedic surgeons. This launch reinforces the company's commitment to advancing pediatric orthopedic care.
OrthoPediatrics Corp (Nasdaq: KIDS) announced participation in the 2021 JMP Securities Life Sciences Conference on June 17, 2021. Key executives, including CEO Dave Bailey, COO and CFO Fred Hite, and Executive Chairman Mark Throdahl, will engage in a fireside chat at 12:00pm ET. An audio webcast of the event will be available on the company's investor relations website, with a replay accessible for 90 days post-event. OrthoPediatrics specializes in pediatric orthopedics, offering 36 surgical systems across trauma, scoliosis, and sports medicine.
OrthoPediatrics Corp. (Nasdaq: KIDS) has completed a leadership transition, appointing David Bailey as the new Chief Executive Officer, succeeding Mark Throdahl, who will remain as Executive Chairman. Throdahl praised Bailey's experience since joining the company in 2007, expressing confidence in his leadership. Bailey emphasized that the company's strategy will remain unchanged, focusing on executing growth plans and delivering innovative products for pediatric orthopedic surgeons to improve children's lives. The company markets 36 surgical systems across key categories in pediatric orthopedics.
OrthoPediatrics Corp. (Nasdaq: KIDS) has launched its RESPONSE™ Neuromuscular Scoliosis System, marking its 36th surgical system introduction. The system, cleared by the FDA in 2020, targets pediatric patients with neuromuscular scoliosis, developed in collaboration with pediatric orthopedic surgeons. This innovative system integrates with existing RESPONSE Scoliosis offerings and aims to enhance surgical efficiency and patient outcomes. OrthoPediatrics focuses exclusively on pediatric orthopedic solutions, distributing in the U.S. and 45 other countries.
OrthoPediatrics Corp. (NASDAQ: KIDS) has reaffirmed its support for the 2021 Pediatric Orthopaedic Society of North America (POSNA) annual meeting, which saw over 400 participants despite COVID-19 challenges. As a Double Diamond Sponsor, the company contributed to educational symposia and scholarships. The press release highlighted its Scoliosis franchise, particularly the ApiFix technology, designed for less invasive scoliosis correction. With 48 patents and a focus on pediatric orthopedics, OrthoPediatrics is dedicated to enhancing treatment options for children.
OrthoPediatrics Corp. (KIDS) reported a 31.2% year-over-year revenue increase for Q1 2021, totaling $21.5 million. Domestic revenue grew by 25.8%, while international revenue surged 55.6%. The company achieved notable revenue gains across various segments: Trauma & Deformity revenue rose 19.2%, Scoliosis by 60.4%, and Sports Medicine/Other by 120.5%. Despite an operating loss of ($6.0 million) and a net loss of ($10.4 million), OrthoPediatrics maintains a strong balance sheet with $78.0 million in cash. The company has raised its 2021 revenue guidance to a range of $94-98 million.
OrthoPediatrics Corp. (Nasdaq: KIDS) will participate in a fireside chat at the 7th Annual Truist Securities 2021 Life Sciences Summit on May 5, 2021. The session will feature company executives including President Dave Bailey, COO and CFO Fred Hite, and CEO Mark Throdahl. The fireside chat will provide insights into the advancement of pediatric orthopedics, showcasing OrthoPediatrics' commitment to improving children's lives through innovative surgical systems. The event will be available via a webcast at 1:00 PM ET, with a replay available for 90 days.
OrthoPediatrics Corp. (NASDAQ: KIDS) will release its Q1 2021 financial results on May 5, 2021, after the market closes. A conference call to discuss these results is scheduled for May 6, 2021, at 8:00 a.m. ET, with dial-in numbers for domestic and international participants. The company focuses exclusively on pediatric orthopedics, offering a broad range of surgical systems across trauma, scoliosis, and sports medicine. Its products are distributed in the U.S. and 44 other countries.
OrthoPediatrics Corp. (Nasdaq: KIDS) announced participation in the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021. Key executives, including President Dave Bailey and CEO Mark Throdahl, will engage in a fireside chat at 12:45 PM ET. The event is accessible via webcast, and a replay will be available for 90 days. OrthoPediatrics, established in 2006, specializes in pediatric orthopedics and offers 35 surgical systems across various categories, including trauma and deformity management, scoliosis, and sports medicine.
OrthoPediatrics Corp. (Nasdaq: KIDS) has successfully performed over 500 ApiFix procedures for treating progressive adolescent idiopathic scoliosis (AIS), marking significant milestones for its innovative technology. The ApiFix offers a less invasive, motion-preserving option without the permanence of fusion, with a typical surgical procedure lasting under two hours and minimal recovery time. The company continues to gather data to establish a new standard for spinal deformity treatment. The ApiFix system is FDA and CE Mark approved, supported by 46 patents worldwide.